Suppliers and packagers for generic pharmaceutical drug: PACLITAXEL

PACLITAXEL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	216874	ANDA	Alembic Pharmaceuticals Limited	46708-620-05	1 VIAL, MULTI-DOSE in 1 CARTON (46708-620-05) / 5 mL in 1 VIAL, MULTI-DOSE	2022-10-20
Alembic	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	216874	ANDA	Alembic Pharmaceuticals Limited	46708-621-17	1 VIAL, MULTI-DOSE in 1 CARTON (46708-621-17) / 16.7 mL in 1 VIAL, MULTI-DOSE	2022-10-20
Alembic	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	216874	ANDA	Alembic Pharmaceuticals Limited	46708-622-50	1 VIAL, MULTI-DOSE in 1 CARTON (46708-622-50) / 50 mL in 1 VIAL, MULTI-DOSE	2022-10-20

Pharmaceutical Paclitaxel: Key Suppliers and Procurement Map

Last updated: April 24, 2026

Who supplies paclitaxel to the pharmaceutical supply chain?

Paclitaxel (drug substance and, in some cases, formulated drug product) is sourced from a mix of specialty APIs, generic injectables supply chains, and custom manufacturing networks. In practice, most procurement flows from API manufacturers, contract manufacturers (for semi-finished bulk), or finished-product registrants that source from controlled upstream API supply.

What supplier types dominate paclitaxel supply?

Paclitaxel supply is concentrated in four supplier categories:

1. API manufacturers (drug substance)
   Provide paclitaxel as sterile or non-sterile API bulk for formulation into injectable and other dosage forms.

2. Semi-finished bulk and sterile manufacturing partners
   Handle drug-product manufacturing steps requiring sterile processes, controlled particle limits, and validated aseptic filling.

3. Finished drug product manufacturers (injectables)
   Sell registered strengths and presentations (often via generic or branded product dossiers), typically sourcing API from one or more qualified API suppliers.

4. Specialty chemical and intermediates suppliers (upstream)
   Provide key intermediates and raw materials used to synthesize paclitaxel, which can affect lead times and capacity risk.

Which suppliers are established in paclitaxel’s market?

The paclitaxel market is supplied by multiple global manufacturers. The list below covers commonly cited API and injectables supply participants used in procurement and dossier-based sourcing.

Common paclitaxel API and drug-product supply participants

Supplier	Supplier type in practice	Likely role in paclitaxel supply chain	Where it shows up in procurement
Sandoz	Finished product / generics	Supplies paclitaxel injectable offerings in multiple markets	Through finished-product distributors and tenders
Hospira (Pfizer)	Finished product	Historical branded/market supply for paclitaxel injectables	Through hospital distribution and tender channels
Teva	Finished product / generics	Paclitaxel injectable supply via generic programs	Through registered product channels
Dr. Reddy’s Laboratories	Finished product / generics	Injectable paclitaxel programs in multiple jurisdictions	Through distributors and tenders
Mylan (Upjohn/Viatris)	Finished product / generics	Paclitaxel injectable supply in generic channels	Through distributor and hospital procurement
Accord Healthcare	Finished product / generics	Paclitaxel injectable supply lines	Through regional tender/distributor networks

API-level sourcing realities

Paclitaxel API supply is tighter than many commodity APIs because the molecule has:

• High manufacturing complexity
• Strong regulatory expectations for impurity profiling, residual solvents, and sterility assurance for final products
• Batch-to-batch consistency requirements driven by oncology dosing and clinical risk tolerance

Procurement teams typically qualify at least two upstream API sources for continuity, but qualification depth varies by tender rules and national dossier structures.

How to map paclitaxel procurement to supplier qualification and lead-time risk

Procurement for paclitaxel usually follows a qualification pattern:

• Step 1: finished-product qualification (for hospital tenders and formulary uptake)
• Step 2: upstream API verification through controlled supplier lists, CoAs, DMFs/ASMFs where applicable, and change-control history
• Step 3: alternates for continuity under supply disruptions

Qualification checkpoints procurement teams use

Checkpoint	What procurement verifies	Why it matters for paclitaxel
API impurity profile	Known genotoxic/critical impurities, batch uniformity	Drives clinical and regulatory acceptability
Sterile manufacturing controls	Aseptic process validation and environmental controls	Paclitaxel injectables are risk sensitive
Particle controls	Sub-visible particle limits and filtration performance	Injectable oncology dosing
Solvent and residual limits	Residual solvents and endotoxin/bioburden controls	Compliance and patient safety
Change-control history	Evidence of controlled changes to synthesis routes or purification	Prevents formulation instability or impurity drift

What dosage-form suppliers typically dominate demand?

In most jurisdictions, the practical procurement unit is the paclitaxel injectable (commonly with solvent systems in the formulation). That shifts market power toward finished-product manufacturers and sterile fill-finish partners, even when API is the real constraint.

Where supplier selection usually matters most

Supplier selection becomes decisive when:

• A tender requires a specific presentation and national registration
• A manufacturer’s supply chain shifts (API substitution, solvent system changes, or filling site changes)
• Sterile manufacturing capacity is constrained
• Distribution contracts lock in lead-time and forecast commitments

Procurement action: how buyers structure supplier redundancy

Most buyers mitigate paclitaxel supply risk using a two-layer redundancy model:

• Layer 1: finished-product redundancy
  Qualify multiple distributors/manufacturers to preserve tender continuity.

• Layer 2: upstream redundancy
  Require that each finished-product option uses qualified API sources with acceptable change-control records.

This structure is particularly important for oncology injectables where substitution is clinically constrained.

Key Takeaways

• Paclitaxel supply is dominated by qualified injectable supply chains, so procurement power often sits with finished-product manufacturers and sterile fill-finish networks, even though API is the upstream constraint.
• Supplier qualification focuses on impurity control, sterile manufacturing assurance, particle controls, and change-control stability.
• Buyers mitigate availability risk with redundancy at two levels: finished-product options and upstream API qualification.

FAQs

1. Is paclitaxel typically purchased as API or as finished injectable?
   Buyers usually procure paclitaxel as a registered injectable product for hospital use, even when upstream API qualification is the underlying constraint.

2. Why does paclitaxel face more supply tightness than many other oncology drugs?
   The molecule requires complex manufacturing with stringent impurity and sterile process expectations.

3. What supplier categories should a buyer qualify for paclitaxel continuity?
   Finished-product manufacturers (and their sterile sites) plus at least two qualified upstream API sources via verification and change-control review.

4. What quality attributes matter most for paclitaxel injectables?
   Impurity profile, sterile manufacturing controls, particle limits, endotoxin/bioburden, and residual solvent compliance.

5. How do tender requirements affect supplier choice for paclitaxel?
   National registration, packaging strength, and presentation requirements often determine acceptable substitutions more than raw API equivalence.

---

References

[1] U.S. Food and Drug Administration (FDA). Drug Safety Communications and labeling information for paclitaxel-containing products. https://www.fda.gov/
[2] European Medicines Agency (EMA). EPAR and related documentation for paclitaxel-containing medicinal products. https://www.ema.europa.eu/
[3] U.S. National Library of Medicine. PubChem Compound Summary for Paclitaxel. https://pubchem.ncbi.nlm.nih.gov/